

Pre Post Deployment Spirometry NASEM Roundtable

Michael J. Morris, M.D. COL (Ret), MC, USA Pulmonary/Critical Care Brooke Army Medical Center

3 October 2019





- "The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Dept. of the Army and Dept. of Defense or the U.S. Government."
- Speaker's Bureau Janssen/GSK





- Screening spirometry in military personnel Anderson DF et al, *Mil Med* 2018; 183; e562–e569.
- Air Force firefighters unpublished
- Asthma unpublished
- Pre/post deployment spirometry (STAMPEDE II) Morris MJ et al, *Respir Care* 2019; 64 (5) 536-544





- 900 patients enrolled (80% male)
- Mean age = 21.6; BMI = 24.3
- Abnormal studies (10.9%)
 - Obstructive = 4.0%
 - Restrictive = 4.9%
 - Mixed = 0.3%
 - Flow volume loop = 2.0%
- Logistic regression analysis
 - Did not correlate with gender, smoking, symptoms, asthma history, or failed APFT
 - Correlated only with elevated BMI



Screening Spirometry



	FVC	FEV ₁	FEV ₁ /FVC	Smoking	APFT Failure	Cough	Dyspnea	Asthma
Normal (n = 802)	97.4%	96.6%	0.84	317 (39.5%)	181 (22.6%)	78 (9.7%)	54 (6.7%)	43 (5.4%)
Abnormal (n = 98)	88.1%*	81.7%*	0.79*	41 (41.8%)	26 (26.5%)	6 (6.1%)	5 (5.1%)	4 (4.1%)
Obstructive (n = 33)	100.8%	80.7%*	0.67*	13 (39.4%)	8 (24.2%)	0	0	0
Restrictive (n = 44)	75.1%*	77.1%*	0.87*	19 (43.2%)	14 (31.8%)	6 (13.6%)	4 (9.1%)	2 (4.5%)

No effect on the probability of an abnormal spirometry result (p=0.56).





Spirometry (n = 58)	Pre-Deploy	% Change Post- Deploy
FEV ₁	101 ± 12%	+ 1.3%
FVC	102% ± 11%	+ 1.5%
FEF ₂₅₋₇₅	93 ± 22%	+ 3.2%

- 3 subjects with decrease in both FVC and $FEV_1 > 10\%$
- 1 subject with decrease in FEV₁/FVC suggesting new onset obstruction
- 2 subjects with > 20% isolated decrease in mid-flows without significant change in FEV₁/FVC ratio.





Spirometry (n = 100)	Pre-Deploy	Post-Deploy	
FEV ₁ (% pred)	98.4 ± 12.8	99.3 ± 14.5	
FVC (% pred)	98.6 ± 13.1	101.5 ± 14.3	
FEV ₁ /FVC	83.4 ± 6.4	80.3 ± 5.4	
FEF ₂₅₋₇₅	95.0 ± 23.2	95.1 ± 24.3	


- Mean time between spirometry = 5.74 years







Post Deployment Changes in Pulmonary Function







- 642 AD military with ICD-9 diagnosis of asthma
- 2009 2015
- Documented spirometry and SWA deployment
- 71 individuals identified with pre- and postdeployment spirometry
 - Mean interval: 1181 days
- 35 identified with pre- and post-deployment spirometry with post-bronchodilator values
 - Mean interval: 1382 days







	Pre/Post FEV ₁	Post-BD FEV ₁
Ν	71	34
Age (yrs)	31.9	32.2
Male	51 (71.8%)	25 (70.6%)
Female	20 (28.2%)	10 (29.4%)
Deployments	1.69	1.71
Deployment Length (days)	201	227



Asthma Spirometry



Value	Pre- Deployment	Post- Deployment	Difference	P-value
FEV ₁ (L)	3.34 (86%)	3.29 (87%)	-0.05 L	0.43
FVC (L)	4.44 (94%)	4.41 (95%)	-0.03 L	0.59
FEV ₁ /FVC	0.75	0.75	0	0.60







Value	Pre- Deployment	Post- Deployment	Difference	P-value
FEV ₁	80%	84%	+4%	0.16
FVC	92%	97%	+5%	0.04
Post-BD FEV ₁	90%	89%	-1%	0.74
Post-BD ΔFEV_1	+12%	+7%	-5%	0.03





- Limited number of AD military with both pre- and post- deployment spirometry (n = 71, only 10% of study patients)
- 82.3% of asthma diagnosis supported by confirmatory testing
- No differences in pre- and post-deployment ACT scores, ICS dosing, or LABA use







- Deploying soldiers from Ft. Hood, Texas
- Primarily tasked to Afghanistan
- Pre-deployment evaluation SRP site
 - Spirometry
 - Impulse oscillometry
 - Respiratory questionnaire
- Enrollment of 1693 soldiers
- 83% male
- Age = 32.2 ± 9.1 years
- $BMI = 27.1 \pm 3.7$
- Never smokers = 64%






STAMPEDE II Pre



	All (n=1693)	Non-Deploy (n=809)	Prior Deploy (n = 884)
FEV ₁ (% pred)	94.8 ± 12.7	92.7 ± 12.3	95.6 ± 12.7
FVC (% pred)	95.5 ± 11.9	93.6 ± 11.3	98.4 ± 12.8
FEV ₁ /FVC	81.7 ± 6.4	80.9 ± 6.5	82.2 ± 6.9
FEF ₂₅₋₇₅ (% pred)	96.6 ± 25.9	94.1 ± 25.3	93.5 ± 26.9
Obstructed (LLN)	190 (11.2%)	89 (11.0%)	101 (11.4%)
Supranormal (FEV ₁)	64 (33.7%)	33 (37.1%)	31 (30.7%)




STAMPEDE II Pre





STAMPEDE II Pre










- More than one third of surveyed solders had a smoking history
- 73% were overweight or obese
- 6.2% reported a history of asthma.
- Abnormal spirometry was found in 22.3% of participants.
 - More asthma (10.1% vs 5.1%, P < .001)</p>
 - Failed physical fitness tests (9.0% vs 4.6%, P < 0.02)
 - Respiratory symptoms (32.8% vs 24.3%, P < 0.001).




Deployment Symptoms



0 = never, $1 = \langle 2x weekly, 2 = 2-5x weekly, 3 = daily$











STAMPEDE II Post



Table 6. Subgroup Analysis of Spirometry Based on Post-Deployment Symptoms

Symptom	Level	Results, mean \pm SD	P, Wilcoxon Test
Dyspnea	Normal	1.37 ± 0.66	.37
	Obstruction	1.49 ± 0.80	
Wheezing	Normal	1.21 ± 0.55	.03
	Obstruction	1.41 ± 0.79	
Cough	Normal	1.65 ± 0.89	.74
	Obstruction	1.59 ± 0.83	
Sputum	Normal	1.38 ± 0.80	.73
	Obstruction	1.42 ± 0.86	
Exercise tolerance	Norm	1.33 ± 0.67	.25
	Obstruction	1.38 ± 0.65	





- Improvement in spirometry and IOS values
- Analysis of obstructed spirometry
 - 33 (3.9%) with pre obstruction
 - 54 (6.4%) with pre/post obstruction
 - 29 (3.4%) with post obstruction
- Pre-deployment obstruction, asthma, smoking, or increased BMI did not demonstrate a reduction in spirometry values post-deployment.
- Frequent wheezing post-deployment was only symptom associated with airways obstruction during deployment (p = 0.026)





PFT Value	% Abnormal
Reduced FEV ₁ /FVC (below 95 th CI)	25.0%
Post-BD $FEV_1 > 12\%$ 1	11.6%
Total lung capacity (TLC) < 80% pred	7.4%
RV/TLC > 35	13.2%
Diffusing capacity (DLCO) < 70%	9.7%

Majority of patients with normal pulmonary function testing

